/ /

  • linkedin
  • Increase Font
  • Sharebar

    Micro-stent may be stand-alone option when topical glaucoma therapy fails

    Long-term results showed improved pressure control, decreased medication burden


    Medication use also decreased from a mean of 2.2 medications preoperatively to 1.3 and 1.5 medications at 6 and 12 months postoperatively. Need for trabeculectomy was avoided in 85% of cases, as adequate control was achieved with the micro-stent.

    “The 12-month DUETTE results showed improved IOP control and a lower medication burden after implantation of the [device],” he said.

    The safety profile reflected a microinvasive procedure. No sight-threatening complications developed. In all cases of cataract progression, investigators noted that patients already had pre-existing cataract preoperatively. All cases of hyphema resolved within 1 month.

    Material, design

    The micro-stent—made of a biocompatible, non-degradable, polyimide material—is implanted using a clear corneal, 1.5-mm incision with an ab interno approach.

    The conjunctiva, sclera, and trabecular meshwork remain intact. The device is designed to use the same outflow pathway as prostaglandin analogues, he noted. 


    Quang H. Nguyen, MD

    E: [email protected]

    Dr. Nguyen is an investigator for Transcend Medical. The CyPass Micro-Stent is an investigational device in the United States.


    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results